Beyond EGFR Mutations: New Study Reveals Why Some Lung Cancer Cells Survive Osimertinib

Coverage, in order

1. 6h ago
   
   OncoDaily obscure study

   Beyond EGFR Mutations: New Study Reveals Why Some Lung Cancer Cells Survive Osimertinib

   A patient-derived model of EGFR-mutant non-small cell lung cancer reveals how resistant and sensitive tumor-cell states can coexist despite sharing the same EGFR driver mutation. Published in Lung Cancer, the

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.